CA2181502A1 - Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract - Google Patents
Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tractInfo
- Publication number
- CA2181502A1 CA2181502A1 CA002181502A CA2181502A CA2181502A1 CA 2181502 A1 CA2181502 A1 CA 2181502A1 CA 002181502 A CA002181502 A CA 002181502A CA 2181502 A CA2181502 A CA 2181502A CA 2181502 A1 CA2181502 A1 CA 2181502A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- digestive tract
- low
- polymer film
- releasable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Abstract
A pharmaceutical preparation in the form of a coated capsule which can release contents of a capsule at a lower part of the digestive tract comprising (a) a hard capsule containing at least an acidic substance, (b) a polymer film soluble at low pH which is formed on a surface of said hard capsule, and (c) an enteric coating film which is formed on a surface of said polymer film soluble at low pH. According to the pharmaceutical preparation of the present invention, any kind of a medicament can be delivered to any desired site between the upper part of the small intestine and the lower part of the large intestine in the digestive tract by controlling the amount of polymer(s) used for the polymer film soluble at low pH and/or by selecting the kind of the polymer film soluble at low pH and/or the acidic substance without any complicated requirements for each medicament.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP183655/1995 | 1995-07-20 | ||
JP18365595 | 1995-07-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2181502A1 true CA2181502A1 (en) | 1997-01-21 |
CA2181502C CA2181502C (en) | 2003-02-11 |
Family
ID=16139614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002181502A Expired - Fee Related CA2181502C (en) | 1995-07-20 | 1996-07-18 | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
Country Status (13)
Country | Link |
---|---|
US (1) | US6309666B1 (en) |
EP (1) | EP0754452B1 (en) |
KR (1) | KR100389602B1 (en) |
CN (1) | CN1076964C (en) |
AT (1) | ATE225165T1 (en) |
CA (1) | CA2181502C (en) |
DE (1) | DE69624047T2 (en) |
DK (1) | DK0754452T3 (en) |
ES (1) | ES2184846T3 (en) |
ID (1) | ID17428A (en) |
PT (1) | PT754452E (en) |
SG (1) | SG80553A1 (en) |
TW (1) | TW514533B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012024767A1 (en) * | 2010-08-25 | 2012-03-01 | Grant Rufus Sparling Ii | Improved enteric active substance delivery |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001511811A (en) * | 1997-02-13 | 2001-08-14 | ボーン ケア インターナショナル インコーポレイテッド | Targeted therapeutic release of vitamin D compounds |
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
CN1296417A (en) | 1998-02-10 | 2001-05-23 | 卫福有限公司 | Preparation with controlled release |
UA69413C2 (en) | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Enteric coated pharmaceutical composition, pharmaceutical composition in form of spheroid beads, method for manufacturing pharmaceutical composition |
US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
UA73092C2 (en) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Tablets with enteric coating and method for their manufacture |
AU5758799A (en) * | 1998-09-25 | 2000-04-17 | Sankyo Company Limited | Hmg-coa reductase inhibitor-containing preparations |
ATE283689T1 (en) * | 1998-09-28 | 2004-12-15 | Warner Lambert Co | DRUG DELIVERY INTO THE SMALL AND LARGE INTESTINE USING HPMC CAPSULES |
JP2000247911A (en) | 1999-02-26 | 2000-09-12 | Hisamitsu Pharmaceut Co Inc | Absorption promoter for large intestine |
EP1197228A4 (en) | 1999-07-02 | 2004-03-10 | Hisamitsu Pharmaceutical Co | Medicinal compositions for treating colorectal cancer |
AU3400501A (en) * | 2000-02-28 | 2001-09-12 | Vectura Ltd | Improvements in or relating to the delivery of oral drugs |
TWI241195B (en) * | 2000-04-10 | 2005-10-11 | Shionogi & Co | Preventive agent for bile acidic diarrhea |
WO2001095912A1 (en) * | 2000-06-16 | 2001-12-20 | Mitsubishi Pharma Corporation | COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED |
US7842308B2 (en) * | 2001-01-30 | 2010-11-30 | Smithkline Beecham Limited | Pharmaceutical formulation |
US7883721B2 (en) * | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
GB0102342D0 (en) * | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
JP4031232B2 (en) * | 2001-11-09 | 2008-01-09 | カプスゲル・ジャパン株式会社 | New capsule |
US7101565B2 (en) | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
US8168170B2 (en) * | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
US7320583B2 (en) * | 2003-04-16 | 2008-01-22 | Frito-Lay North America, Inc | Apparatus and method for producing colored extruded food products |
TW200526274A (en) * | 2003-07-21 | 2005-08-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
GB0320522D0 (en) | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
US20050152884A1 (en) * | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
TW201240679A (en) | 2004-03-12 | 2012-10-16 | Capsugel Belgium Nv | Pharmaceutical formulations |
US20050283097A1 (en) * | 2004-06-18 | 2005-12-22 | Ultrastop Ltd. | Devices and methodologies useful in non invasive termination of pregnancy |
DE102004046102B4 (en) * | 2004-09-23 | 2009-09-03 | Mars Inc. | indicator granules |
GB0427456D0 (en) * | 2004-12-15 | 2005-01-19 | Phoqus Pharmaceuticals Ltd | Formulation for production of capsule shells and capsules |
WO2006130187A1 (en) * | 2005-05-31 | 2006-12-07 | The Iams Company | Feline probiotic lactobacilli |
PL1885383T3 (en) * | 2005-05-31 | 2017-06-30 | Iams Europe B.V. | Feline probiotic bifidobacteria |
US20070014847A1 (en) * | 2005-07-05 | 2007-01-18 | Ahmed Salah U | Coated capsules and methods of making and using the same |
US20070196399A1 (en) * | 2006-02-21 | 2007-08-23 | Shin-Etsu Chemical Co., Ltd. | Enteric-coated preparation covered with enteric coating material for site-specific delivery of drug to site within the small intestine |
JP5799299B2 (en) | 2007-02-01 | 2015-10-21 | ザ・アイムス・カンパニーThe Iams Company | Method for reducing inflammation and stress in mammals using glucose antimetabolite, avocado or avocado extract |
KR101752080B1 (en) | 2007-12-28 | 2017-06-28 | 임팩스 라보라토리즈, 인코포레이티드 | Controlled release formulations of levodopa and uses thereof |
GB0808537D0 (en) | 2008-05-12 | 2008-06-18 | Archimedes Dev Ltd | Compositions |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
WO2010080730A2 (en) * | 2009-01-09 | 2010-07-15 | Mayo Foundation For Medical Education And Research | Methods and materials for delivering bile acids |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
US10653631B2 (en) | 2011-09-07 | 2020-05-19 | Roland SAUR-BROSCH | Optimal colon targeting technology |
EP2753310B1 (en) | 2011-09-07 | 2021-03-24 | Roland Saur-Brosch | Formulation for the controlled release of one or several substances in the digestive tract of a mammal |
DE102011082716A1 (en) * | 2011-09-14 | 2013-03-14 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Indicators element used in cell culture vessel for determining pH value of substance comprises polymeric material and indicator dye |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
KR102266091B1 (en) | 2013-10-07 | 2021-06-17 | 임팩스 라보라토리즈, 인코포레이티드 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
CN108884171B (en) | 2016-04-08 | 2022-02-18 | 株式会社大赛璐 | Cellulose ester and molded article thereof |
EP3485879A1 (en) * | 2017-11-17 | 2019-05-22 | Maat Pharma | Pharmaceutical oral formulation comrpsing bacteria |
JP2021528483A (en) * | 2018-05-03 | 2021-10-21 | エムダブリュ エンキャップ リミテッド | Dosage form for delivery of drug to the lower gastrointestinal tract |
JPWO2020071395A1 (en) * | 2018-10-02 | 2021-09-02 | クオリカプス株式会社 | Hard capsules with improved strength and their manufacturing methods |
KR102106244B1 (en) * | 2019-10-30 | 2020-05-04 | 한국광기술원 | Capsule type photodynamic therapy apparatus with anchor |
US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
WO2023174722A1 (en) * | 2022-03-15 | 2023-09-21 | Evonik Operations Gmbh | Pre-functionalized hard shell capsule with accelerated drug release at ph value 5 to 5.5 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4012444A (en) * | 1969-07-08 | 1977-03-15 | Allen & Hanburys Limited | 5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof |
US5188840A (en) * | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
JPS6299322A (en) | 1985-10-24 | 1987-05-08 | Shinjiro Tsuji | Novel dosage form of hard capsule agent |
IL77186A0 (en) * | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
DE3812799A1 (en) * | 1988-04-16 | 1989-10-26 | Sanol Arznei Schwarz Gmbh | ORGANIC PREPARATION FOR THE PURPOSES OF AN ACTUATED ACTIVE INGREDIENTS AND METHOD OF PREPARING THEM |
US5252576A (en) * | 1988-07-18 | 1993-10-12 | Yamasa Shoyu Kabushiki Kaisha | 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient |
ATE109973T1 (en) * | 1989-05-11 | 1994-09-15 | Chugai Pharmaceutical Co Ltd | ORAL PREPARATION FOR ADMINISTRATION TO SPECIFIC SITES OF THE INTESTINE. |
JPH0674206B2 (en) * | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | Controlled release formulation and process for producing |
JP2773959B2 (en) * | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | Colon release solid preparation |
JP3122478B2 (en) | 1991-02-19 | 2001-01-09 | 帝國製薬株式会社 | Lower gastrointestinal release oral formulation |
JPH0624962A (en) | 1992-07-09 | 1994-02-01 | Green Cross Corp:The | Enteric sustained release solid pharmaceutical preparation |
ES2119818T3 (en) | 1992-08-13 | 1998-10-16 | Teikoku Seiyaku Kk | ORAL PREPARATION FOR RELEASE IN THE LOWER DIGESTIVE TRACT. |
KR0157280B1 (en) | 1992-11-06 | 1998-11-16 | 나까토미 히로타카 | Oral pharmaceutical preparation release in the lower digestive tract |
JPH06256166A (en) | 1993-01-06 | 1994-09-13 | ▲寛▼治 ▲高▼田 | Pharmaceutical preparation for controlling release of medicine |
JPH0710745A (en) | 1993-06-22 | 1995-01-13 | Tanabe Seiyaku Co Ltd | Oral preparation for release-starting time control type intestinal delivery |
-
1996
- 1996-07-13 SG SG9610256A patent/SG80553A1/en unknown
- 1996-07-15 US US08/680,753 patent/US6309666B1/en not_active Expired - Fee Related
- 1996-07-18 ES ES96401604T patent/ES2184846T3/en not_active Expired - Lifetime
- 1996-07-18 DE DE69624047T patent/DE69624047T2/en not_active Expired - Fee Related
- 1996-07-18 DK DK96401604T patent/DK0754452T3/en active
- 1996-07-18 CA CA002181502A patent/CA2181502C/en not_active Expired - Fee Related
- 1996-07-18 PT PT96401604T patent/PT754452E/en unknown
- 1996-07-18 AT AT96401604T patent/ATE225165T1/en not_active IP Right Cessation
- 1996-07-18 EP EP96401604A patent/EP0754452B1/en not_active Expired - Lifetime
- 1996-07-19 TW TW085108781A patent/TW514533B/en not_active IP Right Cessation
- 1996-07-19 KR KR1019960029252A patent/KR100389602B1/en not_active IP Right Cessation
- 1996-07-22 ID IDP962071A patent/ID17428A/en unknown
- 1996-07-22 CN CN96107185A patent/CN1076964C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012024767A1 (en) * | 2010-08-25 | 2012-03-01 | Grant Rufus Sparling Ii | Improved enteric active substance delivery |
US9782354B2 (en) | 2010-08-25 | 2017-10-10 | II Grant Rufus Sparling | Enteric active substance delivery |
Also Published As
Publication number | Publication date |
---|---|
DK0754452T3 (en) | 2003-02-03 |
EP0754452A3 (en) | 1998-01-21 |
EP0754452B1 (en) | 2002-10-02 |
CA2181502C (en) | 2003-02-11 |
ES2184846T3 (en) | 2003-04-16 |
US6309666B1 (en) | 2001-10-30 |
CN1142944A (en) | 1997-02-19 |
DE69624047D1 (en) | 2002-11-07 |
SG80553A1 (en) | 2001-05-22 |
MX9602863A (en) | 1997-09-30 |
ID17428A (en) | 1997-12-24 |
DE69624047T2 (en) | 2003-08-14 |
ATE225165T1 (en) | 2002-10-15 |
KR970005279A (en) | 1997-02-19 |
TW514533B (en) | 2002-12-21 |
CN1076964C (en) | 2002-01-02 |
EP0754452A2 (en) | 1997-01-22 |
PT754452E (en) | 2003-02-28 |
KR100389602B1 (en) | 2003-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2181502A1 (en) | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract | |
AU1488295A (en) | Pharmaceutical composition | |
MX9500885A (en) | Pharmaceutical preparation for oral administration. | |
CA2383220A1 (en) | Controlled release pellet formulation | |
DE3686936T2 (en) | ENTERAL DELIVERY SYSTEM ACTIVE AT THE TARGET ORGAN. | |
CA2312710A1 (en) | Sustained release formulation containing three different types of polymers and tablet formed therefrom | |
CA2230314A1 (en) | Pharmaceutical formulations | |
DE69630375D1 (en) | PHARMACEUTICAL DOSAGE FORM FOR RELEASE IN THE COLON | |
CA2352389A1 (en) | An oral formulation for gastrointestinal drug delivery | |
CA2268175A1 (en) | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery | |
DE69619668T2 (en) | PHARMACEUTICAL DOSAGE FORM WITH MULTIPLE GAROL-SOLUBLE POLYMER COATING FOR ACTIVE SUBSTANCE DELIVERY IN THE COLON | |
CA2346988A1 (en) | Pharmaceutical formulation comprising omeprazole | |
AU6770490A (en) | Solid pharmaceutical compositions containing cimetidine | |
CA2221356A1 (en) | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids | |
CA2290531A1 (en) | Pharmaceutical formulation of omeprazole | |
CA2148465A1 (en) | Oral Pharmaceutical Preparation Releasable in the Lower Digestive Tract | |
CA2145513A1 (en) | Pharmaceutical Tablet Capable of Liberating One or More Drugs at Different Release Rates | |
DE69816951D1 (en) | Preparation containing cefaclor or cephalexin with a modified release matrix | |
CA2377916A1 (en) | Taste masked pharmaceutical liquid formulations | |
CA2183862A1 (en) | Stabilized composition for oral administration of peptides | |
CA2041044A1 (en) | Large Intestinal Dissociative Polypeptide Series Oral Formulation | |
CA2000932A1 (en) | Oral pharmaceutical controlled release multiple unit dosage form | |
CA2121038A1 (en) | Oral preparation for release in lower digestive tracts | |
EP0425298A3 (en) | Sustained-release preparation of basic medical agent hydrochloride | |
CA2271569A1 (en) | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed | ||
MKLA | Lapsed |
Effective date: 20060718 |